Multiple studies have found that actionable secondary germline mutations identified by TGP are prevalent in cancer patients, with 10–15% of patients undergoing TGP having a pathogenic or likely pathogenic mutation in an actionable hereditary cancer risk gene [6, 7]. The gene discussed is TGM4; the disease is cancer.